NICE has confirmed that its new aligned pathway with the Medicines and Healthcare products Regulatory Agency is now fully open, a move designed to bring medicines to patients in England up to three to six months sooner. The change follows commitments in the government’s 10 Year Health Plan for England and Life Sciences Sector Plan to speed access to new treatments and improve the way decisions on licensing and value are made. ([nice.org.uk](https://www.nice.org.uk/news/blogs/mhra-nice-pathway-opens-for-business-everything-you-need-to-know-to-get-started?utm_source=openai))
Parallel decisions are intended to reduce delays for industry and the NHS
Under the new approach, NICE and the MHRA will work more closely so that decisions can run in parallel rather than sequentially. NICE says the aligned pathway and its improved Integrated Scientific Advice service are now open for business from 1 April 2026, with the aim of giving companies greater certainty while helping patients receive approved medicines earlier. ([nice.org.uk](https://www.nice.org.uk/news/blogs/mhra-nice-pathway-opens-for-business-everything-you-need-to-know-to-get-started?utm_source=openai))
The pathway is also intended to support earlier NHS entry for medicines and, for industry, a longer period of rebate-free sales before the Voluntary Scheme for Branded Medicines Pricing, Access and Growth applies. NICE said the first treatments are already going through the aligned pathway, and the first guidance is expected in June 2026. ([nice.org.uk](https://www.nice.org.uk/news/blogs/mhra-nice-pathway-opens-for-business-everything-you-need-to-know-to-get-started?utm_source=openai))
What the new model means for patients
The policy is part of a wider effort to make access to innovation faster and more consistent across the health service. NICE has said the coordinated system should help bring its decision-making closer to MHRA licensing, reducing the gap between regulatory approval and NHS availability. The organisation has also linked the reform to its wider health technology agenda, including a push for smarter spending and faster access to proven innovations. ([nice.org.uk](https://www.nice.org.uk/news/blogs/mhra-nice-pathway-opens-for-business-everything-you-need-to-know-to-get-started?utm_source=openai))
The announcement comes after NICE set out other 2026 priorities, including the National HealthTech Access Programme. That programme has already identified capsule sponge tests for detecting oesophageal cancer and AI tools for identifying prostate and breast cancer as the first topics to go through the new route. ([nice.org.uk](https://www.nice.org.uk/news/articles/faster-fairer-access-to-healthtech-under-new-national-programme))
Early pipeline already includes cancer diagnostics and AI tools
NICE says the HealthTech programme is aimed at making a small selection of high-impact technologies available consistently across the NHS, rather than only in some parts of the country. The initial topics include capsule sponge tests for detecting abnormal cells associated with Barrett’s oesophagus and early oesophageal cancer, as well as AI tools that analyse tissue samples to help detect breast and prostate cancer. ([nice.org.uk](https://www.nice.org.uk/news/articles/faster-fairer-access-to-healthtech-under-new-national-programme))
According to NICE, the capsule sponge test offers a less invasive alternative to endoscopy and may help free up resources for urgent investigations. The AI tools, meanwhile, are designed to highlight suspicious regions and grade tumours, supporting pathologists by reducing routine workload and improving the speed of reporting. ([nice.org.uk](https://www.nice.org.uk/news/articles/faster-fairer-access-to-healthtech-under-new-national-programme))
A broader push to modernise access to treatment
Taken together, the measures point to a wider shift in how the NHS may adopt medicines and health technologies in the coming months. The emphasis is on earlier decisions, clearer pathways for developers, and more consistent access for patients across England and Wales. NICE says the intention is to end postcode variation and ensure that clinically and cost-effective innovations reach the health service more quickly. ([nice.org.uk](https://www.nice.org.uk/news/blogs/mhra-nice-pathway-opens-for-business-everything-you-need-to-know-to-get-started?utm_source=openai))
For now, the message from NICE is that the system is moving from planning to implementation. With the aligned pathway now live, the first test will be whether parallel decisions can deliver the promised speed without undermining the evidence base that underpins NHS access decisions. ([nice.org.uk](https://www.nice.org.uk/news/blogs/mhra-nice-pathway-opens-for-business-everything-you-need-to-know-to-get-started?utm_source=openai))
Sursa foto: Imagine generată AI
